Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia.
Racil
Zdenek
Z
Klamova
Hana
H
Voglova
Jaroslava
J
Faber
Edgar
E
Razga
Filip
F
Zackova
Daniela
D
Buresova
Lucie
L
Cetkovsky
Petr
P
Mayer
Jiri
J
D000328:Adult; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D013163:Splenomegaly / Q000150:complications*; D017211:Treatment Failure
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate